ADPT (Adaptive Biotechnologies) ROCE %: -16.28% (As of Mar. 2026)

What is Adaptive Biotechnologies ROCE %?

Adaptive Biotechnologies ADPT +12.34% 73 ROCE % is -16.28% as of Mar. 2026. GuruFocus rates ADPT with a GF Score™ of 73/100 and a GF Value™ of $10.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Adaptive Biotechnologies's annualized ROCE % for the quarter that ended in Mar. 2026 was -16.28%.

Adaptive Biotechnologies (NAS:ADPT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Adaptive Biotechnologies ROCE % Related Terms

Adaptive Biotechnologies ROCE % Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies ROCE % Chart

Adaptive Biotechnologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-22.77

-25.20

-32.05

-29.18

-11.03

Adaptive Biotechnologies Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-24.92	-21.89	12.33	-10.24	-16.28

73GF Score

Adaptive Biotechnologies Corp ADPT

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Adaptive Biotechnologies ROCE % Calculation

Adaptive Biotechnologies's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-47.679	/	( ( (539.376 - 98.053)	+	(512.736 - 89.915) )	/ 2 )
	=	-47.679	/	( (441.323	+	422.821)	/ 2 )
	=	-47.679	/	432.072
	=	-11.03 %

Adaptive Biotechnologies's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-68.504	/	( ( (512.736 - 89.915)	+	(505.943 - 87.011) )	/ 2 )
	=	-68.504	/	( ( 422.821	+	418.932 )	/ 2 )
	=	-68.504	/	420.8765
	=	-16.28 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -16.28% mean?

Adaptive Biotechnologies (ADPT) has a ROCE % of -16.28% as of Mar. 2026.

Is Adaptive Biotechnologies' ROCE % too high?

Adaptive Biotechnologies' current ROCE % is -16.28%. Overall, Adaptive Biotechnologies has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Adaptive Biotechnologies' ROCE % compare to GRAL and WGS?

Adaptive Biotechnologies' ROCE % of -16.28% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Diagnostics & Research company?

A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Adaptive Biotechnologies's current ROCE % is -16.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Adaptive Biotechnologies stock overvalued right now?

Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.06, compared to a current price of $19.34 — trading 92.2% above its estimated fair value. The current ROCE % is -16.28%. Adaptive Biotechnologies' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current ROCE % is -16.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $19.34 is trading 92.2% above its estimated GF Value™ of $10.06. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

ROCE %: -16.28%
GF Value™: $10.06 vs. price of $19.34 (92.2% above fair value)
GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies GRAL WGS NEO PSNL CDNA VCYT OPK TWST CSTL FLGT TMO DHR SHSE:603259 XSWX:LONN IDXX A WAT NTRA IQV ILMN

Other Exchanges 1HM:Germany

Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

73GF Score

Get the complete analysis for ADPT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.34

Price

$10.06

GF Value

View ADPT Analysis

See ROCE % data for all stocks →